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 ABSTRACT
Background: In the haemodynamically unstable 
patient the method of treatment of acute renal failure 
is still largely controversial. The purpose of our study 
was to compare slow extended dialysis with continuous 
haemodiafiltration in the critical patient with indication 
for renal replacement therapy and haemodynamic 
instability. Patients and Methods: This is a cohort study 
comparing in 63 ventilated critical patients a 12 month 
period when only continuous haemodiafiltration was 
used (n=25) with an equal period of slow extended 
dialysis (n=38). Our primary objective was to evaluate 
the impact of the dialytic procedure on cardiovascular 
stability in those patients. As secondary aims we con-
sidered system coagulation/thrombosis and predictors 
of mortality. In the two groups we analysed the first 
session performed, the second session performed and 
the average of all the sessions performed in each 
patient. Results: In these patients, mortality in the 
intensive care unit was high (68% in the continuous 
haemodiafiltration group and 63% in the slow extend-
ed dialysis group). We did not find any association 
between the dialytic technique used and death; only 
the APACHE score was a predictor of death. Slow 
extended dialysis was a predictor of haemodynamic 
stability, a negative predictor of sessions that had to 
be interrupted for haemodynamic instability, and a 
predictor of achieving the volume removal initially 
sought. Slow extended dialysis was also associated 
with less coagulation of the system. Conclusions: Our 
data suggested that slow extended dialysis use was 
not inferior to continuous haemodiafiltration use in 
terms of cardiovascular tolerability.
Key-Words:
Acute renal failure; cardiovascular tolerance; con-
tinuous haemodiafiltration (CHDF); haemodynamic 
instability; slow extended dialysis (SLED)
 INTRODUCTION
Acute renal failure in critical care is a worrisome 
condition, associated with significant mortality. It is 
usually a part of multiorgan failure with an expres-
sive burden in the intensive care unit.
In the haemodynamically unstable patient the 
method of management of renal failure is still largely 
controversial1 -10. In a critical care unit setting, several 
variations of the classic modalities of renal replacement 
therapy are emerging for the treatment of those 
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patients. The so-called sustained low-efficiency dialysis 
(SLED), extended daily dialysis, or even hybrid renal 
replacement technique, differs from conventional hae-
modialysis mainly in the length of treatment (duration 
over 6 hours) and in blood and dialysate pump veloc-
ities (lower than 200 and 300 ml/min, respectively)11 -13. 
This hybrid technique that brings together conven-
tional haemodialysis and slow continuous therapies 
features is becoming increasingly used and appears to 
add advantages from both kinds of techniques with 
minimisation of respective inherent limitations. Data 
are pointing to the fact that it can potentially replace 
traditional continuous therapy, given the lesser cost 
and logistic and technical complications11,12,14-19.
Continuous haemodiafiltration (CHDF) has both 
diffusive and convective clearances and is considered 
the most complete form of continuous therapy20. 
There are studies comparing continuous haemofiltra-
tion (CHF) with SLED or CHDF with intermittent 
haemodialysis, but to our knowledge there has not 
yet been any comparison between SLED and CHDF.
In our intensive care unit SLED has become the 
renal replacement therapy of choice for haemody-
namically unstable patients, but previously only 
continuous renal replacement therapy was available. 
In this cohort study we compared patients submitted 
only to CHDF and patients submitted only to SLED. 
Our primary objective was to evaluate the impact of 
the dialytic procedure (SLED and CHDF) on cardio-
vascular stability in those patients. As secondary 
aims we considered system coagulation/thrombosis 
episodes and predictors of mortality.
We compared, in 63 ventilated critical patients of 
that unit with indication for renal replacement 
therapy and haemodynamic instability, a 12 month 
period when only CHDF was used (GROUP I, n=25) 
with an equal period of SLED (GROUP II, n=38).
 PATIENTS AND METHODS
The study was carried out in a 14-bed medical-
surgical intensive care unit. In 2003 all patients pre-
senting haemodynamic instability and need for renal 
replacement therapy (RRT) were treated with CHDF. 
SLED was performed in all such patients starting in 
February 2004. The study period was 2003-2005.
Inclusion criteria for this study were: 1) admission to 
the intensive care unit, 2) need for renal replacement 
therapy defined as one of the following – oliguria (uri-
nary output < 200ml in 12 hours), urea > 180mg/dl, fluid 
overload and pulmonary oedema, uraemic syndrome 
(encephalopathy, pericardial effusion, feeding intoler-
ance), metabolic acidosis with pH<7.15, K>6.5mmol/l or 
rapidly progressing, Na<115mmol/l and 3) presence of 
hypotension (mean arterial pressure <80mmHg) and/or 
vasopressor support. Critical patients with indication for 
conventional haemodialysis (meaning need for RRT but 
with mean arterial pressure >80mmHg without vasopres-
sor support) were therefore excluded from the study.
The decision to treat was evaluated daily, consid-
ering the haemodynamic status of the patient, 
diuresis and laboratory parameters. Whenever appro-
priated, patients who recovered and needed further 
renal replacement therapy were treated on conven-
tional dialysis and left the study.
CHDF was performed using a Gambro Prisma® 
monitor, AN 69 M60 or M100 filter, dialysis solution 
Hemosol BO® with potassium added as needed, blood 
flow rate (Qb) =150 to 180 ml/min, mean dialysate 
flow rate (Qd) =1730±630ml/h, mean replacement 
fluid (predilution) infusion rate =1260±340 ml/h. In 
Group II SLED was obtained using Gambro AK200® 
monitors, with Polyflux 14L® filtre, Qb =150 to 200 
ml/min, Qd =300 ml/min. Time on SLED was 6 to 12 
hours per session. Non-fractioned heparin was used 
in both techniques, in a dose of 1000 units bolus fol-
lowed by 500 units/h, adjusted to an activated partial 
thromboplastine time of 1.5 times the control value.
Since we are dealing with procedures of different 
durations (continuous versus non -continuous), in 
order to have a comparable unit to a SLED session, 
we defined as an “isolated session” of CHDF the one 
realised in each 24 -hour period (beginning at the 
time of the initiation of CHDF for each patient).
We used as comparative terms in each of the two 
groups of patients (CHDF versus SLED): A – the first ses-
sion performed; B – the second session performed (thus 
overcoming the initial adaptation period allowing a com-
parison in what we designated the steady state); C – the 
average of all the sessions performed in each patient.
Variables studied were number of sessions in 
which the ultrafiltration (UF) volume sought was 
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achieved; number of haemodynamic instability epi-
sodes – defined as episodes of pressure lowering 
with need for therapeutic intervention (fluids, UF 
changing, increase or beginning of vasopressor) –; 
number of haemodynamic instability episodes that 
led to stopping of the dialytic technique; number of 
filter/circuit thrombosis and mortality. These vari-
ables were adjusted for age, severity scoring 
indexes (APACHE II and SAPS II), sepsis, heart fail-
ure, hourly UF rate, total UF rate and heparin units 
per hour.
Using multivariate analysis we analysed predictors 
of haemodynamic instability, predictors of interrup-
tion of dialytic procedure, predictors of achieving 
the volume removal clinically judged as adequate 
and tolerable for that patient, predictors of system 
coagulation and intensive care unit death.
  Statistical analysis
Data are expressed as frequencies for categorical 
variables, mean values with SD for normally distrib-
uted variables. Comparison between groups was 
performed by the Student t-test, Mann-Whitney U 
(numerical variables) and chi -square tests (categor-
ical variables). Multivariate analysis was performed 
by linear regression models, for the average of all 
sessions, and logistic regression models, when the 
first and second sessions isolated were considered, 
in which we integrated the enter model with a selec-
tion of variables based on relevant clinic criteria. 
Using the Hosmer and Lemeshow test we confirmed 
the quality of the adjustment in all models.
Statistical analyses were performed with the SPSS 
system 14.0 (SPSS Inc., Chicago, IL). For all com-
parisons a p<0.05 was considered significant.
 RESULTS
Table II
Technical characteristics of first, second and the average of all sessions






















Total UF (ml) 2577±1430 1644±1278 0.0142 2563±433 1814±174 0.0291 2346±1260 1730±910 0.0281
UF/hour (ml/h) 127 ml/h 238 ml/h 0.0011 154 280 0.0062 130 261 <0.011
Heparin/hour (U/h) 380 U/h 487 U/h 0.0142 391 481 0.0282 394 474 0.050
UF achieved = intended 14 (56%) 33 (87%) <0.0012 7 (44%) 23 (89%) <0.0012 48% 89% <0.0012
Haemodynamic instability 16 (64%) 15 (40%) 0.0573 7 (44%) 5 (19%) 0.0753 60% 28% 0.0042
Stopping for haemodynamic instability 4 (16%) 4 (11%) 0.5233 3 (19%) 1 (4%) 0.1013 25% 12% 0.0652
Filter/circuit thrombosis 9 (36%) 3 (8%) 0.0053 6 (38%) 3 (11%) 0.0403 34% 8% 0.0002
Univariate analysis by groups considering first session, second session and average of all sessions 1Student t, 2Mann-Whitney U, 3χ2
Table I







Age 59.2±18 66.9±15 0.069
Gender (M/F) 13/12 18/20 0.719
Under vasopressors 57.8% 62% 0.878
Oliguria 48% 64% 0.069
Sepsis 36% 36.8% 0.946
Heart failure 8% 13.2% 0.052
APACHE II 29.5±8 27.9±10 0.051
SAPS II 55.5±23 66.9±19 0.043
Admission days 12.5±13 23.4±25 0.048
Mechanical ventilation days 7±8 18.5±21 0.010
TOTAL OF SESSIONS 64 112
SESSIONS / PATIENT 2.6±1.8 2.9±2.3
REAL DURATION / SESSION 19±6 7.5±2.5
The values in the centre columns correspond to the respective averages or percentages
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Tables III
Multivariate analyses of the parameters studied
A. Independent variable: haemodynamic instability







p B 95%CI (B) p
SLED -1.876 0.15 0.02_1.05 0.056 -1.194 0.30 0.04_2.53 0.270 -0.491 -0.784_-0.198 0.001
Age 0.017 1.02 0.98_1.05 0.337 -0.005 0.99 0.94_1.05 0.842 0.001 -0.004_0.007 0.601
APACHE -0.025 0.97 0.90_1.05 0.529 -0.049 0.95 0.85_1.07 0.412 -0.007 -0.019_0.006 0.275
SAPS II 0.020 1.02 0.98_1.06 0.258 0.043 1.04 1.00_1.09 0.078 0.004 -0.002_0.010 0.184
Sepsis 0.265 1.30 0.41_4.15 0.654 1.072 2.92 0.57_15.01 0.199 0.133 -0.054_0.319 0.160
UF/session 0.000 1.00 1.00_1.00 0.355 0.000 1.00 1.00_1.00 0.560 0.000 0.000_0.000 0.036
UF/hour 0.000 1.00 0.99_1.00 0.910 -0.007 0.99 0.98_1.00 0.185 0.000 -0.001_0.001 0.805
First and second sessions – logistic regression analysis: model p=0.276 and p=0.207, respectively. Average of all sessions – multiple linear regression analysis: model p=0.001; R2=0.34
B. Independent variable: interruption of dialytic procedure







p B 95%CI (B) p
SLED -4.669 0.01 0.00_0.80 0.040 -7.900 0.00 0.00_20.33 0.156 -0.289 -0.532_-0.045 0.021
Age -0.058 0.94 0.86_1.04 0.232 0.069 1.07 0.92_1.25 0.381 0.000 -0.005_0.004 0.932
APACHE -0.085 0.92 0.76_1.11 0.373 -0.369 0.69 0.44_1.07 0.101 -0.007 -0.018_0.003 0.168
SAPS II 0.084 1.09 0.96_1.23 0.174 -0.030 0.97 0.87_1.08 0.572 0.004 -0.001_0.008 0.130
Sepsis 0.097 1.10 0.09_13.57 0.939 4.563 95.87 0.16_58329 0.163 0.152 -0.003_0.307 0.055
UF/session -0.006 0.99 0.99_1.00 0.067 -0.001 1.00 1.00_1.00 0.146 0.000 0.000_0.000 0.008
UF/hour 0.026 1.03 0.99_1.07 0.167 0.010 1.01 0.98_1.04 0.470 0.006 -0.001_0.001 0.979
First and second sessions – logistic regression analysis: model p=0.003 and p=0.028, respectively. Average of all sessions – multiple linear regression analysis: model p=0.001; R2=0.36
C. Independent variable: achieving planned volume removal







p B 95%CI (B) p
SLED 4.297 73.50 4.44_1216.34 0.003 5.516 248.74 2.50_24716 0.019 0.542 0.275_0.809 0.000
Age -0.023 0.98 0.93_1.02 0.340 0.103 1.11 1.01_1.22 0.034 -0.001 -0.006_0.005 0.841
APACHE 0.105 1.11 0.99_1.24 0.062 0.108 1.11 0.91_1.36 0.296 0.006 0.006_0.017 0.327
SAPS II -0.023 0.98 0.93_1.02 0.316 -0.038 0.96 0.90_1.03 0.280 0.000 -0.005_0.006 0.861
Sepsis -0.935 0.39 0.08_1.91 0.247 -4.292 0.01 0.00_0.78 0.037 -0.134 -0.304_0.036 0.119
UF/session 0.001 1.00 1.00_1.00 0.024 0.000 1.00 1.00_1.00 0.336 0.000 0.000_0.000 0.031
UF/hour -0.002 1.00 0.99_1.010 0.681 0.002 1.00 9.9_1.01 0.774 0.000 -0.001_0.001 0.599
First and second sessions – logistic regression analysis: model p=0.001 and p=0.001, respectively. Average of all sessions – multiple linear regression analysis: model p≤0.001; R2=0.41
D. Independent variable: system coagulation







p B 95%CI (B) p
SLED -0.946 0.39 0.07_2.01 0.259 -2.373 0.093 0.01_0.75 0.025 -0.228 -0.393_-0.062 0.008
Sepsis -0.347 0.71 0.14_3.56 0.674 0.017 1.017 0.19_5.33 0.984 -0.095 -0.242_0.052 0.202
UF/hour -0.009 0.99 0.98_1.00 0.087 0.001 1.00 1.00_1.00 0.556 0.000 -0.001_0.001 0.928
Heparin/hour -0.005 0.99 0.99_1.00 0.018 0.004 1.00 1.00_1.01 0.176 -0.000 -0.001_0.000 0.047
First and second sessions – logistic regression analysis: model p=0.002 and p=0.191, respectively. Average of all sessions – multiple linear regression analysis: model p=0.002; R2=0.25
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During the study period 907 patients were admit-
ted. Of these, 195 (21.5%) presented a markedly 
altered renal function (serum creatinine >2.5 mg/dl 
or urea >100 mg/dl or urinary output <400 cc /24 
hours) and 140 (15.4%) underwent a renal replace-
ment technique.
Sixty three patients met inclusion criteria and 
were enrolled. They were divided into 2 groups: 
Group I (CHDF) included 25 patients that underwent 
64 dialytic sessions with an average of 2.6 sessions 
for patient; and Group II (SLED) 38 patients were 
submitted to 112 dialytic sessions with an average 
of 2.9 sessions for patient.
Using univariate analysis the two groups of 
patients were similar in terms of demographic char-
acteristics and comorbidities. Patients submitted to 
SLED had significantly higher SAPS II severity scor-
ing index, admission days and, consequently, 
mechanical ventilation days (Table I).
Analysing the first, the second and the average 
of all sessions (Table II), patients submitted to SLED 
had lower total UF but a higher hourly UF and a 
higher percentage of patients achieved the desired 
UF. A lower percentage of patients under SLED suf-
fered circuit or filter thrombosis. When the average 
of all sessions per patient was assessed, it was also 
shown that patients treated with SLED had a lower 
percentage of haemodynamic instability. There was 
no significant difference regarding the earlier inter-
ruption of the technique due to haemodynamic 
instability, by univariate analysis.
Using multivariate analysis we observed:
• The number of sessions with haemodynamic 
instability episodes was dependent on the dia-
lytic procedure used and UF/session. Concerning 
all sessions performed, the average number of 
haemodynamic instability episodes decreased 
51% when SLED was used instead of CHDF, with 
that result adjusted for age, severity scoring 
indexes, sepsis, heart failure, total volume of 
UF per session and UF per hour (Table III A).
• Premature stopping as a consequence of hae-
modynamic instability was again dependent on 
SLED and UF/session (Table III B).
• Regarding predictors of achieving the planned 
volume removal, UF achieved = desired was 
once more dependent on SLED and UF/session 
(Table III C).
• Filter/circuit thrombosis was dependent on SLED 
and heparin units/hour. SLED use was a protec-
tor factor of coagulation of the system, as well 
as the heparin units per hour, adjusted to UF 
volume per hour and for the presence of sepsis 
(table III D).
A comparative study of cardiovascular tolerability with slow extended dialysis 
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Table IV
Independent variable: mortality in the intensive care unit.
All Sessions (176 sessions in 63 pts)
B 95%CI (B) OR p
SLED 0.147 0.030_45.21 1.16 0.937
Age 0.010 0.957_1.065 1.01 0.721
Gender (M/F) 0.818 0.471_10.91 2.27 0.307
APACHE 0.118 1.003 -1.262 1.12 0.043
SAPS II -0.35 0.918_1.016 0.97 0.183
Sepsis 0.719 0.356_11.84 2.05 0.422
Heart failure 0.444 0.145_16.80 1.56 0.714
UF/session 0.001 0.999_1.002 1.00 0.515
UF/hour 0.005 0.992_1.002 1.00 0.430
UF achieved=intended 0.952 0.062_108.5 2.59 0.617
Haemodynamic instability 2.407 0.550_224.57 11.11 0.117
Stopping for haemodynamic instability 5.400 0.560_87560 221.5 0.077
Total heparin 0.000 1.000_1.000 1.00 0.353
Logistic regression analysis: model p=0.006
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In these patients, mortality in the ICU was high 
(68% in GROUP I and 63% in GROUP II). We did not 
find any association between the dialytic technique 
used and death. APACHE score was the only predic-
tor of death obtained (Table IV).
 DISCUSSION
SLED consists of an adaptation of conventional 
intermittent haemodialysis, aimed to be low efficient, 
as it in fact was at the beginning of dialysis history. 
This low efficacy is achieved using low blood and 
dialysate pump velocities, and treatment length is 
extended, allowing a reduced hourly fluid removal. 
The name SLED comes from the Arkansas group 
(UAMS, Little Rock) who in 1998 described the use 
of a Fresenius machine 2008H® with reduced 
dialysate and blood flow rates for 12 -hour nocturnal 
treatments12-15.
It has been increasingly reported that SLED has 
the advantages of intermittent haemodialysis (high 
efficacy, simplicity, lower cost, no need for industry 
prepared replacement fluids) plus the advantages of 
continuous renal replacement therapy (prolonged 
and smooth metabolic control with consequent 
reduced haemodynamic instability). Intuitively, con-
tinuous therapy is in line with the concept of critical 
care management as implying achieving homeosta-
sis, giving time for organ recovery.
Data on SLED in the intensive care unit setting 
are still limited. The haemodynamic stability report-
ed here agrees with previous descriptions. Our 
approach is very similar to the one used by Kumar 
et al11. They compared SLED not with CHDF but with 
continuous haemofiltration and found good cardio-
vascular tolerability and significant less anticoagula-
tion requirements with the first. Other studies by 
the same group and others have confirmed those 
findings12,16-19.
In this study, SLED was well tolerated in the 
majority of the cases, allowing an adequate control 
of volume status (as well as of solutes and electro-
lytes, outside the range of this study).
Regression analyses showed that the use of SLED 
was a positive predictor of haemodynamic stability, 
and also that fewer sessions had to be suspended 
for haemodynamic instability. Likewise, SLED 
appeared as a predictor for achieving the UF volume 
initially desired.
Dialysis efficacy described in the literature is at 
least non-inferior to that described with continuous 
therapies using high dialysate and substitution flu-
ids11,15,18, a factor implicated in the prognosis of 
critically ill patients with renal impairment21,22.
Compared to continuous therapies, a lower anti-
coagulation use is the rule with SLED, due to a 
shorter dialytic period. Moreover, in this study, SLED 
use appeared as a protector factor of coagulation 
of the system. One could argue that in the present 
work there is less thrombosis with SLED because 
the time was less and time was not considered a 
variable. Considerable less total heparin was used 
in that group, which can have some beneficial impact 
on such patients with high risk for haemorrhagic 
complications as the ones considered here.
One obvious advantage of SLED is that, due to 
the length of treatment, at least two patients can be 
treated with the same dialysis monitor in the same 
24-hour period. It is difficult to establish when to 
stop a continuous renal replacement therapy. In 
patients submitted to SLED the decision to switch to 
a conventional intermittent haemodialysis is easier.
Lower costs and workload are other important 
related issues23,24. The economic burden is signifi-
cantly less with SLED; likewise this technique was 
easily learned and accepted by the nurses, and 
required less monitoring and intervention than CHDF, 
as observed previously by different authors11,12.
Despite the repeated effort that has been made 
over the last few decades in order to demonstrate 
the advantages of continuous therapy in the critical 
patient with acute renal failure, and especially after 
the widespread use of biocompatible membranes, no 
benefit has been shown concerning survival and renal 
function recovery of that modality compared with 
conventional haemodialysis5 -9,24 -26, as was recently 
seen in a multicentre randomised trial with 360 
critical patients27. The proven prognostic factor in 
terms of therapeutic intervention in such patients 
seems to be dialysis dose and not the dialytic modal-
ity per se21,22. The belief that took root in the 
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supremacy of continuous therapy came from various 
circumstances, not only the theoretically superior 
cardiovascular tolerability and the benefit of convec-
tion clearance of the inflammatory sepsis media-
tors28, but perhaps also the freeing of nephrologists 
from intensive care units12. In the era of biocompat-
ible membranes, the first statements have been 
refuted, with studies showing the primordial impor-
tance of adsorption and the lack of clinical relevance 
of the removal of mediators (with no distinction 
between pro- or anti-inflammatory ones and minimal 
clearance compared with the endogenous one)29 -33.
 LIMITATIONS OF THIS STUDY
This was an observational study comparing two 
different treatments in two groups of patients with 
similar baseline characteristics. A prospective and 
randomised analysis is needed to confirm these 
results.
The dose of therapy was not controlled, although 
the dialysate and substitution fluids used in this 
study in CHDF were in line with the standards recom-
mended21.
 CONCLUSION
Despite this being a comparative uncontrolled 
study, in this group of critical patients SLED use was 
definitely not inferior to CHDF in terms of cardiovas-
cular tolerability. SLED appeared as a predictor of 
haemodynamic stability, a negative predictor of ses-
sions that had to be interrupted for haemodynamic 
instability, and a predictor of achieving the UF vol-
ume initially intended. SLED seemed also to protect 
against the coagulation of the system.
We have to wait for appropriately designed stud-
ies to shed definite light into what is common 
practice but which so far has insufficient evidence: 
the predominant use of continuous techniques for 
renal replacement therapy in haemodynamically 
unstable patients, with its considerable burden on 
economic and practical issues.
Conflict of interest statement. None declared.
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